TTR Amyloidosis
58 programs · 56 companies
Programs
58
Companies
56
Trials
36
MOAs
36
CDK2iALKiCFTRmodHPK1iJAK1/2iCAR-T BCMABETiUSP1iCAR-T CD19EGFRi
Drugs
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| PFE-3703 | Phase 1/2 | CDK2 | ||
| Miriosocimab | Phase 1 | PARP | ||
| LLY-4358 | Phase 3 | B7-H3 | ||
| ABB-7516 | Phase 3 | PD-L1 | ||
| Fixanesiran | Preclinical | RET | ||
| Fixazanubrutinib | Phase 2 | PI3Kα | ||
| GIL-2445 | Phase 2/3 | PSMA | ||
| Sovanaritide | Phase 3 | TNFα | ||
| GMA-729 | Phase 2 | BCL-2 | ||
| Talasotorasib | Preclinical | APOC3 | ||
| Bemaderotide | Phase 3 | BCL-2 | ||
| Lisonesiran | Phase 1/2 | PARP | ||
| Voxabrutinib | Phase 1/2 | EZH2 | ||
| Pemilemzoparlimab | Phase 1/2 | MALT1 | ||
| Pexazanubrutinib | Preclinical | TROP-2 | ||
| Olpazasiran | Preclinical | DLL3 | ||
| Sovalucimab | NDA/BLA | TROP-2 | ||
| ZNT-6525 | Phase 1 | CDK2 | ||
| Nidarelsin | Phase 2/3 | BCL-2 | ||
| MBX-6478 | Phase 1/2 | MET | ||
| NKT-8115 | Phase 2 | SGLT2 | ||
| KAL-3067 | Phase 2/3 | JAK2 | ||
| Zanufotisoran | Phase 1/2 | ALK | ||
| GLY-2161 | Phase 1/2 | PD-L1 | ||
| Zorilucimab | NDA/BLA | PSMA | ||
| AMP-8001 | NDA/BLA | PARP | ||
| Tezesotorasib | Phase 2/3 | DLL3 | ||
| AVI-386 | Phase 1/2 | HER2 | ||
| Kematenlimab | Phase 3 | FGFR | ||
| Tiracagene | Phase 3 | SOS1 | ||
| Miritinib | Phase 2/3 | BET | ||
| Gozerapivir | Phase 2 | CD38 | ||
| BIO-6952 | NDA/BLA | KRASG12D | ||
| Gozemavacamten | Approved | CD20 | ||
| MOM-980 | Preclinical | TYK2 | ||
| Doxasertib | Preclinical | AuroraA | ||
| Nirarapivir | Approved | GIP-R | ||
| Olpacilimab | Phase 1 | RET | ||
| ONC-9294 | Approved | TIM-3 | ||
| Talaglumide | NDA/BLA | SGLT2 | ||
| 418-9392 | NDA/BLA | MALT1 | ||
| Zanuratamab | Phase 1 | TIM-3 | ||
| NAT-2164 | Phase 1/2 | RET | ||
| IMM-6534 | Phase 1/2 | Nectin-4 | ||
| Suranaritide | Phase 1/2 | C5 | ||
| Sovarapivir | Preclinical | Cl18.2 | ||
| MAG-3823 | Phase 1 | WEE1 | ||
| Sotomavacamten | NDA/BLA | TIM-3 | ||
| Zoriratamab | Preclinical | BET | ||
| Voxanesiran | Phase 1 | CD47 | ||
| MAN-3628 | Phase 1 | FXIa | ||
| Nidanesiran | Preclinical | RET | ||
| CHI-IIT-303 | Phase 2/3 | LAG-3 | ||
| PRI-IIT-560 | Phase 1/2 | KRASG12D | ||
| Liralucimab | Phase 3 | APOC3 | ||
| WAT-2618 | Preclinical | IL-17A | ||
| AMY-7629 | Phase 2/3 | KIF18A | ||
| YB-3612 | Phase 1 | HER2 |
Trials (36)
| NCT | Drug | Phase | Status |
|---|---|---|---|
| NCT07045848 | PFE-3703 | Phase 1/2 | Recruiting |
| NCT05322076 | LLY-4358 | Phase 3 | Terminated |
| NCT03778407 | ABB-7516 | Phase 3 | Active |
| NCT07561331 | ABB-7516 | Phase 3 | Not yet recr... |
| NCT04704245 | Fixazanubrutinib | Phase 2 | Completed |
| NCT04647786 | GIL-2445 | Phase 2/3 | Completed |
| NCT06861752 | GMA-729 | Phase 2 | Active |
| NCT03045181 | Talasotorasib | Preclinical | Not yet recr... |
| NCT03375686 | Talasotorasib | Preclinical | Active |
| NCT03751729 | Bemaderotide | Phase 3 | Completed |
| NCT03563605 | Lisonesiran | Phase 1/2 | Active |
| NCT03031485 | Pemilemzoparlimab | Phase 1/2 | Active |
| NCT04181153 | Pemilemzoparlimab | Phase 1/2 | Completed |
| NCT03233604 | Olpazasiran | Preclinical | Recruiting |
| NCT08779347 | Sovalucimab | NDA/BLA | Recruiting |
| NCT07171947 | Nidarelsin | Phase 2/3 | Completed |
| NCT08944735 | MBX-6478 | Phase 1/2 | Terminated |
| NCT05981308 | MBX-6478 | Phase 1/2 | Not yet recr... |
| NCT05761209 | NKT-8115 | Phase 2 | Not yet recr... |
| NCT05015449 | KAL-3067 | Phase 2/3 | Not yet recr... |